Enabling Cost-Efficient CGT Manufacturing.

More than just cost, it’s about scalability, speed to market, and long-term viability.

Building a sustainable cost model across development, clinical, and commercial stages is a critical priority. Learn how IRO is achieving cost-efficiency in CGT manufacturing.

Learn More Connect with us

Address the Cost Drivers & Reduce Cost Per Dose by Up to 40%

Most manufacturing costs come from three areas:

Consumables (viral vector, reagents, media): ~50%
Labor (direct and indirect): ~40%
Infrastructure (facilities and equipment): ~10%

Because these costs are determined at the start of the development process, reversing them later is difficult and expensive. That’s why integrating the right technology at the start is essential to reducing long-term manufacturing costs.

IRO® outperforms legacy systems: reducing all key cost drivers and lowering the total cost of goods.

The cost model illustrated above is a representative example based on a lentiviral CAR-T process, which illustrates key cost drivers and strategies for economic sustainability. Actual values will vary by therapy, platform, and process design (Source 1)

How IRO Achieves Cost-Efficiency.

Get Better Biology Results

Legacy systems often deliver poor transduction and weak cell expansion, forcing developers to overspend on consumables or accept high out-of-spec rates.

IRO® achieves higher transduction efficiency:

Reduce viral vector use
Deliver consistent biology
Lower consumable spending per batch

See Biological Data

Automate Manual Processes

Manual workflows demand expensive, high-skill labor. This limits scalability and raises the risk of errors and hidden costs – making reliable commercialization harder to achieve.

IRO® automates & deskills manufacturing operations:

Cut high-skill labor dependency
Minimize human errors
Reduce batch failure rate

Reduce Labor Costs

Operate at a Lower Cleanroom Grade

Grade A/B cleanrooms are essential for open, manual workflows but remains costly to build and scale as therapy programs expand.

IRO® enables manufacturing in Grade C/D spaces:

Close and automate fluid transfer
Reduce contamination risks
Facilitate multi-site manufacturing

Increase Throughput

Reduce Labor Costs by
50-70%

IRO® automates activation, transduction and expansion – minimising manual interventions that drive extra QA oversight.

By removing manual tasks like archiving, IRO® deskills operations, reduces hands-on time and operator dependency, and cuts labor costs by 50-70%.

Decrease your cleanroom size, with IRO®.

Increase Throughput Per Square Feet ~1000 doses per year in 1000 sq ft.

The IRO® platform boosts throughput by enabling multiplexed, closed-system manufacturing in Grade C/D environments – reducing cleanroom demands and allowing up to 5× more batches in the same space than legacy systems.

This accelerates timelines, expands production, and scales capacity without costly facility buildouts.

Learn more

Build Commercial Viability into Your Development from Day One

Connect with an Ori team member to learn more about how you can effectively build a sustainable manufacturing cost model.

Oribiotech Ltd 2025 © All rights reserved. Oribiotech Ltd is registered in England and Wales. "Ori”, “Ori Biotech”, "Iro" and the O icon are registered trademarks of Oribiotech Ltd.
Company registration 09757696